VitalHub's $100M ARR Milestone Looks Real-But the Next 10% Growth Rate Will Decide the Stock

VitalHub's $100 million ARR milestone matters, but durability is the real question

VitalHub has cleared the $100 million ARR mark, but the stock now depends on whether 10% organic growth can hold up quarter after quarter. The company closed at $101.5 million of ARR, while total revenue reached $31.7 million, up 33% year over year. That is a meaningful milestone. Still, public markets usually reward sustained execution more than headline size alone.

Recurring revenue is roughly 80% of the business. In practical terms, VitalHub already operates more like a subscription business than a pure project vendor. The latest quarter also showed a solid earnings base, with $8.2 million of adjusted EBITDA and a 26% adjusted EBITDA margin.

The bull case is straightforward: if organic ARR growth, margins, and cash conversion keep improving together, this business starts to look less like a series of acquired pieces and more like a repeatable platform.

The counterpoint is that recent growth has also included acquisitions and foreign-exchange effects, which can make the top line look stronger than the underlying customer engine.

Recurring revenue is the strength, but mix still complicates the growth story

VitalHub's recurring base is real, but investors still need proof that the revenue machine is getting cleaner. The company closed at $101.5 million of ARR with 10% organic ARR growth, while total revenue rose 33%. That gap is at the center of the debate. Recurring revenue or term license and support was $24.5 million, or 77% of total revenue. So the recurring foundation is solid, but a meaningful minority of revenue still sits outside that bucket.

What the numbers are actually showing

That mix matters because not every dollar of revenue carries the same predictability. Services, hardware, and other revenue reached $4.1 million, up from $2.7 million a year ago, and management said services revenue is variable and harder to forecast from quarter to quarter. That does not make the business weak. It does mean the headline growth rate can be helped by items that are less stable than subscription renewals.

A similar distinction applies to ARR. Management broke down year-over-year ARR growth into organic growth of 10%, acquisition growth of 15%, and a foreign-exchange benefit. Investors focused on durability will want to keep looking through the acquisition and currency effects to see whether the core customer base continues to expand on its own.

Profitability is improving, which matters

Adjusted EBITDA rose from $5.6 million in Q1 2025 to $8.2 million in Q2 2026, with a 26% adjusted EBITDA margin. That suggests VitalHub is not just growing louder; it is becoming more profitable at scale.

Watch these signals over the next few quarters:

• Whether organic ARR growth stays around double digits.
• Whether recurring revenue remains a large and stable share of total revenue.
• Whether adjusted EBITDA margins keep improving without extra one-time boosts.
• Whether Buddy adds strategic value without distracting from ongoing integration work.

If those checks keep getting cleared, VitalHub has a credible case for a better-quality multiple. If not, the stock may remain viewed as promising, but still mixed.

Buddy Healthcare is the next proof point for integration and strategy

Buddy is the next execution test. VitalHub has already said the larger businesses it acquired midway through 2025 are nearly fully integrated, so this deal is less about buying size for its own sake and more about showing that the integration playbook works again in a different country mix and a newer workflow niche.

The price structure deserves attention

VitalHub paid €8.6 million up front, plus up to €4.5 million in earnouts. That structure is reasonably disciplined for this stage of the story. The upfront amount is large enough to matter, while the earnout ties part of the consideration to future performance. On a pro forma basis, Buddy also takes VitalHub to roughly $106.0 million of ARR, which means the market now has a slightly larger business to underwrite and slightly higher expectations for execution.

The strategic case fits VitalHub's broader platform

Buddy also appears to fit naturally into VitalHub's existing product story. The company said the acquisition expands patient journey optimization capabilities, which aligns with VitalHub's broader care coordination, patient engagement, and operational intelligence platform. Geographically, Buddy already has presence in Finland and the UK, giving VitalHub a more tangible foothold in Europe.

Integration is now the stock debate

The bullish read is that Buddy can grow faster with access to VitalHub's larger platform and sales reach. The more cautious read is that integration, customization, longer selling cycles, or management distraction could slow things down. Over the next few quarters, clean execution matters more than the milestone photo op.